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Abstract
Objectives/purpose: The costs attributable to antimicrobial resistance (AMR) remain theoretical and largely unspecified.
Current figures fail to capture the full health and economic burden caused by AMR across human, animal, and
environmental health; historically many studies have considered only direct costs associated with human infection from a
hospital perspective, primarily from high-income countries. The Global Antimicrobial Resistance Platform for ONE-Burden
Estimates (GAP-ON€) network has developed a framework to help guide AMR costing exercises in any part of the world
as a first step towards more comprehensive analyses for comparing AMR interventions at the local level as well as more
harmonized analyses for quantifying the full economic burden attributable to AMR at the global level.
Methods: GAP-ON€ (funded under the JPIAMR 8th call (Virtual Research Institute) is composed of 19 international networks
and institutions active in the field of AMR. For this project, the Network operated by means of Delphi rounds, teleconferences
and face-to-face meetings. The resulting costing framework takes a bottom-up approach to incorporate all relevant costs
imposed by an AMR bacterial microbe in a patient, in an animal, or in the environment up through to the societal level.
Results: The framework itemizes the epidemiological data as well as the direct and indirect cost components needed to build
a realistic cost picture for AMR. While the framework lists a large number of relevant pathogens for which this framework could
be used to explore the costs, the framework is sufficiently generic to facilitate the costing of other resistant pathogens,
including those of other aetiologies.
Conclusion: In order to conduct cost-effectiveness analyses to choose amongst different AMR-related interventions at local
level, the costing of AMR should be done according to local epidemiological priorities and local health service norms. Yet the
use of a common framework across settings allows for the results of such studies to contribute to cumulative estimates that
can serve as the basis of broader policy decisions at the international level such as how to steer R&D funding and how to
prioritize AMR amongst other issues. Indeed, it is only by building a realistic cost picture that we can make informed decisions
on how best to tackle major health threats.
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Background
AMR costs - the limitation of current macro and micro
estimates
In recent years, numerous global institutions including the
United Nations [1], World Health Organization (WHO) [2],
EU commission [3, 4], World Bank [5], Food and Agriculture
Organization of the United Nations (FAO) [6], Organization
for Economic Cooperation and Development (OECD) [7, 8],
as well as national governments such as that of the United
Kingdom [9, 10] have acknowledged the importance of
quantifying the costs of antimicrobial resistance (AMR).
While older studies focussed on costs to health ser-
vices, more recent studies have included many other
costs that AMR imposes on society more widely. These
costs derive from the prolongation of illness and in-
creased levels of mortality, work absenteeism and re-
duced labour efficiency, disruption in international
trade, reduced livestock production [11].
The more publicised estimates of the cost of AMR have
been at the macro-economic level, with forecasts far into
the future, using extrapolation and projection from math-
ematical modelling. The results of these studies have been
staggering. The impact of AMR over the years until 2050
is estimated by the World Bank to be within the same
order of magnitude as that of the major 2008 global finan-
cial crisis [5]: even in the optimistic low-AMR scenario,
the simulated losses of world output exceed $1 trillion an-
nually after 2030 and reach $2 trillion annually by 2050
[9]. The estimated loss in economic output attributable to
AMR, if no interventions are implemented, will be 0.14%
of global GDP every year. Overall, AMR threatens to roll-
back economic and food security gains made over the past
50 years [6] with developing countries being dispropor-
tionately more affected [10]. Sustainable development
goals relating to poverty, childhood survival, and develop-
ment could be jeopardised, with an additional 28 million
people estimated to fall into extreme poverty by 2050
compared to 2017 [5].
While useful for giving a sense of the scale and high
cost of inaction globally, these are rough, top-down esti-
mates, based on numerous parameters with significant
data gaps and thus requiring many assumptions. Such
estimates are of limited use for understanding the full
cost of AMR at the local level or for making decisions
about how to tackle AMR in an economically optimal
manner. The nature of the current data also hinders our
ability to make appropriate trade-offs between policy op-
tions. Where estimates have been made on a micro level,
they have looked mainly at costs derived from the hu-
man health burden imposed by AMR, ignoring indirect
costs and costs derived from resistance in animals and
the environment [2]. This again limits the use of such
estimates to make comparisons amongst potential policy
and practice interventions and to inform policy.
The GAP-ON€ network is funded through the Joint
Programming Initiative on Antimicrobial Resistance
(JPIAMR) 8th call as part of the Virtual Research Initia-
tive 2018 [12]. Its purpose is to bring together experts in
the AMR field in order to identify essential AMR costs
-- taking a global, One Health perspective -- that could
be used to conduct economic analyses bottom-up, to in-
form local decisions, and to build a more nuanced over-
all cumulative cost picture.
Methods
Expert consultation
Expert consultation took place across the GAP-ON€ net-
work, which includes 19 smaller networks and institutions,
comprising human and veterinary infectious diseases physi-
cians and microbiologists, experts in AMR burden estima-
tion, food safety, health-economics, international law, as
well as infection control experts, clinical epidemiologists,
statisticians, and health information librarians.
The costing framework was constructed by means of tele-
conferences, Delphi rounds and a face-to-face meeting, to
reach consensus on the perspective of the framework, the
list of relevant pathogens, applicable costs, epidemiological
data requirements, and data quality dimensions. Interim re-
ports and feedback were managed through electronic ex-
change. A REDCap survey tool [13] was used to quantify
views on key issues. Decisions were made using consensus
methods. At each step, consensus was defined as > 80% of
the panel agreeing with < 10% disagreeing. Where consen-
sus was not reached initially, refinements and discussion
continued until a qualifying level of agreement could be
reached. Overall, two teleconferences were held (June and
September 2019) before the face-to-face meeting (Verona,
Italy, 24–25 September 2019), followed by the 4 Delphi
rounds, and one more TC (January 2020).
Definition of AMR
The focus of this work is currently limited to bacterial
resistance to antibiotics. We maintain the term “anti-
microbial resistance” to highlight that this work can later
be extended to antifungal, antiviral and antiparasitic re-
sistance. The framework focusses on the costs associated
with colonization or infection by single or multiple re-
sistant pathogens, as opposed to its antibacterial sensi-
tive counterpart.1
For the purposes of this costing exercise, colonization
was defined as the presence of bacteria from a non-
1In some cases, comparison to a non-infected population is more rele-
vant, in particular where there have been certain types of preventive
measures. For example, if vaccination prevents all future drug-resistant
and susceptible infections, the harm of drug-resistance as well as infec-
tions in general is eliminated, and therefore the most appropriate com-
parison would calculate the cost impact of resistant infections relative
to no infection..
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sterile specimen (nasal swabs, urine, skin, sputum etc.)
in a sufficiently high concentration that it can be de-
tected, but without causing signs or symptoms of dis-
ease. Colonization can persist for days to years, and a
person or animal colonized with a drug-resistant organ-
ism may transmit it to other humans/animals; it may not
always impose additional costs.
Infection was defined as clinically and (ideally) micro-
biologically confirmed disease, including identification
of an invasive pathogen from a specimen combined
with infection-specific symptoms; it generally imposes
costs within both human and animal health settings at
some level.
Selection of most relevant pathogen-drug pairs
The starting point for the selection process was the
WHO list of priority antibiotic-resistant bacteria [14].
In addition to this list, all bacteria resistant to drugs be-
lieved to be most relevant for human, animal, and plant
health were added by consensus methods as described
above.
Selection of sectors
This work includes all of primary setting in which anti-
biotics are used, and where there is potential for trans-
mission of resistant bacteria (and resistance genes) [15]
(Fig. 1).
Results
The resulting framework consists of the epidemiological
data and the cost components that need to be collected
to build a credible picture of AMR-costs from the local
level (Fig. 2).
Epidemiological data components
AMR pathogens can cause either colonization or disease
in human or animal health, and can be transmitted
within and between One Health areas (Table 1).
Probabilities can be estimated based on the epidemio-
logical data collected (Tables 2, 3 and 4). Incidence and
prevalence are both important, as are both colonisation
and infection, and the probability of colonisation leading
to infection. These data should be derived from proper
Fig. 1 Settings in which antibiotics are used and potential for transmission of resistance bacteria (and resistance genes) [15]
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surveillance studies or from other relevant study designs
(e.g. longitudinal studies to estimate probability of tran-
sition from colonised to infected status) [18]. If available,
estimates surrounding the potential for transmission
across settings and transmission rates within settings
(human to human or animal to animal transmission)
should also be considered (see Fig. 1).
Transmission of resistance between pathogens
The literature confirms the presence of similar strain
types, clones, resistance genes and associated mobile gen-
etic elements across human, animal and environmental
health in different permutations and combinations where
two or more elements of the One Health triad have been
assessed [19]. However, transmission dynamics and direc-
tionality have yet to be ascertained and some assumptions
may have to be made if such estimates are still unavailable
at the time of the cost evaluation exercise.
Adapting the cost framework to the antibiotic resistance
scenario
The costs associated with resistance depend on the anti-
biotic to which resistance has developed as well as other
contextual factors. Some potential scenarios include the
following:
1. Single drug resistance
Resistance emergence to a drug that was previously ef-
fective and widely used, but where there are equally ef-
fective and safe alternatives that are readily available; in
this case the costs will mainly revolve around more ex-
pensive treatment, more diagnostics, more frequent
side-effects/lower tolerability, and longer hospital admis-
sion (i.e. mainly health care costs and R&D costs).
2. Multi-drug resistance
Resistance emergence to drugs, where equally effect-
ive and safe alternatives are not readily available, but
the alternative drug(s) becomes more readily available
as transmission increases; here the costs need to
cover all of the above, plus those associated with
worsening infection, possibly more often resulting in
death, acquiring a more expensive treatment, side-
effects/lower tolerability (i.e. health care costs, some
individual productivity loss, and R&D costs).
3. Pan-drug resistance
Resistance emergence to a last resort antibiotic (creat-
ing a pan-resistant pathogen); here opportunity costs
with regards to avoiding high-risk treatments should be
considered, the costs/burden beyond the health sector
will become more pertinent, like lost productivity and
trade, less tourism, expedited R&D, etc. (i.e. assume pro-
gressive economic lockdown beginning at an effective
reproduction number > 1, as seen in the current
COVID-19 crisis).
Cost data summary (see tables for more detailed cost
itemisation)
Cost burden of AMR on humans (Table 5)
Direct costs associated with care in each of the
relevant health care settings should be considered
(e.g. long-term care facilities, outpatient visits, in-
patient stays, intensive care, etc.). Indirect costs deriv-
ing from the time away from work for patients and
carers, informal care by others and their loss of prod-
uctivity, should also be included. Costs related to
healthcare avoidance should also be considered.
Fig. 2 the GAP-ON€ framework
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Table 1 Antimicrobial resistant bacteria with cost implications in human health or in animal health and production
Important routes of transmission and the role of the environment as a reservoir of infection are indicated
1D = disease occurs due to the organism(s), C = no disease but costs associated with colonisation; H = human, A = animal, E = environment, Y = yes
2In the context of mycobacterial infection, MDR is defined as resistance to at least isoniazid and rifampin and XDR as resistance to isoniazid and rifampin and at
least 3 of the 6 classes of aminoglycosides, polypeptides, fluoroquinolones, thioamides, cycloserine, and para-aminosalicyclic acid
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Table 2 Epidemiological data necessary to build a “One-Health” cost model of AMR
Data element Data items
Prevalence of colonisation (Human Health) Proportion of individuals colonised by drug-resistant pathogens, by subgroups (please see text)
at the time of health care access
Proportion of individuals colonised by drug-resistant pathogens, by subgroups at point
prevalence studies
Prevalence of colonisation (Animal Health) Proportion of food animals colonised by drug-resistant pathogens post-slaughter
Prevalence of colonisation (Environment) Presence/absence of drug-resistant pathogens in water, soil and air
Relevant to Human health:
• Proportion of healthcare facility or home surfaces contaminated with resistant microorganisms
(implies choice of relevant surfaces)
• Abundance and diversity of drug-resistant pathogens in health facility/household effluent
Relevant to Animal health:
• Proportion of animal housing, abattoir and food preparation surfaces contaminated with resistant
microorganisms (implies choice of relevant surfaces)
• Abundance and diversity of drug-resistant pathogens in farming, abattoir and food preparation
entities (restaurants & food processing plants) effluent
The Environment:
• Abundance and diversity of drug-resistant pathogens per volume/quantity of water, soil or
air measured.
Prevalence of infection (Human Health) Number of patients with infection, out of overall number of patients in the health care setting
in that specific subgroup, at the time of assessment
Prevalence of infection (Animal Health) Number of animals with infection, out of overall number of animals in the veterinary care/farm setting
in that specific subgroup, at the time of assessment
Incidence of colonisation (Human Health) Number of new colonisations over an appropriate denominator (implies choice of denominator:
see Table 2 in [16])
e.g. in outbreaks of KPC in NICUs, the number of new colonisations is also taken into account [17]
For example, number of unique cases of colonised Clostridium difficile cases identified over 1000
patient-days (i.e. incident rate)
Incidence of colonisation (Animal Health) Number of new colonisations out of animals not colonised
Incidence of infection (Human Health) Number of patients with new infection caused by a pathogen resistant to 1st line, 2nd line,
3rd line antimicrobials, or MDR, by an appropriate denominator (implies choice of denominator:
see Table 2 in [16]), by subgroup
Incidence of infection (Animal Health) Number of animals with new infection caused by a pathogen resistant to 1st line, 2nd line,
3rd line antimicrobials, or MDR, by an appropriate rate denominator (implies choice of
denominator), by subgroup
Table 3 Probabilities associated with colonisation necessary in a “One-Health” cost model
Data element Probability
Morbidity (Human health) Probability of developing infection in colonised individuals,
Probability of contact precautions/isolation when colonised
Probability of lower quality care when colonised or of missed care opportunity
(e.g., surgical prophylaxis not administered in patients known to be colonised)
Probability of undergoing diagnostic tests
Probability of non-standard surgical prophylaxis
Probability of being treated even in absence of infection, due to known colonisation status
(increase in selection pressure related to environmental contamination)
Lower quality of life
Morbidity (Animal health) For companion animals, probability of being screened for colonisation with AMR pathogens
(e.g. MRSA) in referral veterinary practices.
Probability of developing infection in colonised animals
Probability of surveillance of faecal samples for MDR organisms under public health programmes
Mortality (Animal health) Probability of the animal being slaughtered due to colonisation with resistant pathogen.
Screening (Humans / animals) Probability of starting a screening programme when there is a colonised patient (Number
of colonised patients to trigger a screening programme) (humans / animals)
Bi-directional Transmission of colonisation
between One Health Areas
Probability of each of 6 possible broad paths between One Health areas, and within-area
probability of transmission (e.g. between LTCF and hospitals and vice versa)
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Cumulatively, any loss in productivity due to absence
or disabilities related to resistant infection should also
be included.
Cost burden of AMR on animals (Tables 6 and 7)
Direct costs related to the treatment of companion
animals and animals in the food chain should be in-
cluded. Ideally the effect on the quality of life of the
owner of companion animals lost to resistant infec-
tions would also be considered. Indirect costs associ-
ated with resistance in food chain animals should be
considered at the level of the individual farmer as
well as at the sector-wide level if there is transmis-
sion that affects food chain supply (or if resistance
in isolated cases decreases the overall demand for
those food products). The different species of com-
panion animals (dogs, cats, rabbits, birds, and others)
and of food chain animals (ruminants, poultry, pigs,
aquaculture, and others) should be considered
individually.
Cost burden of AMR on the environment (Table 8)
Environment here accounts for water, soil and air as well
as plants and crops affected by environmental pollution
with antibacterials and drug-resistant microorganisms
from contaminated manure, pharmaceutical manufactur-
ing waste, hospital waste, wastewater treatment facilities,
untreated human waste, waste and runoff from aquacul-
ture, livestock, and plant-based food production and
processing facilities [20].
While the costs associated with treating resistant
infection do not generally apply to wildlife, the
knock-on costs to species elimination, the undermin-
ing of ecosystems, and other related costs should be
considered [21].
Discussion
The need for bottom-up costings of AMR
AMR is not a disease, with its own recognisable signs
and symptoms and clearly associated health burden and
epidemiological parameters. Rather it refers to species
that have acquired drug resistance mechanisms, that
have replicated, and overgrown other species that can
colonize or infect people, animals, or the environment
causing negative effects. The emergence of resistance is
often due to selective pressure of antibiotic use, or dur-
ing the acquisition of DNA from other species or strains,
rendering the strain capable of resisting the inhibitory
activity of some antibiotic (e.g. plasmid-mediated mech-
anisms of resistance). An infection that has not been a
threat for many decades, over time can become resistant
to currently available therapies, and potentially all exist-
ing therapies, and therefore become a threat again. This
change within known existing pathogens, and the fact
that one pathogen may be responsible for multiple types
of infections (e.g. from UTI to CNS abscesses), can make
AMR difficult to understand and address within the pol-
itical sphere as well as within public discourse [2]. In
addition, the slow emergence of the AMR problem
makes it easily ignored in the present, and left to be ad-
dressed at a later time (which does not happen with rap-
idly spreading pathogens such as the SARS-CoV-2 virus,
which has received immediate global attention and
major resources).
Table 4 Probabilities associated with infection necessary in a “One-Health” cost model
Data element Probability
Mortality (overall)
(Human and animal health)
Probability of dying WITH a MDR infection, for a patient/animal infected
(by the subgroups defined in “epidemiology”)
Treatment efficacy of 2nd line, 3rd line etc. drugs
Mortality (attributable)
(Human and animal health)
Probability of dying FROM an MDR infection, for a patient/animal infected
(by the subgroups defined in “epidemiology”)
Treatment efficacy of 2nd line, 3rd line etc. drugs
Morbidity (Human and animal health) Probability of developing long term consequences (e.g chronic or recurrent
infections, long term disability from ICU stay, lower QoL, etc) from AMR infections,
out of all patients infected
Probability of developing adverse events, if treated with 2nd, 3rd etc. line drugs
Longer hospital stay in patients/animals with AMR infections, compared to those
with the same, but not AMR, infection
Longer ICU stay for patients/animals with AMR infections
Additional diagnostic procedures for drug resistant
infections (Human and animal health)
Probability of undergoing additional diagnostic procedures (e.g. imaging to
diagnose site of infection or foci of distant infectious metastatic foci,
FollowupFollow-up blood cultures, etc)
Screening (Humans / animals) Probability of starting a screening programme when there is an infected
patient/animal (Number of colonised patients to trigger a screening
programme) (humans / animals)
Insurance Probability of having an insurance to cover extra AMR costs (Please
note that pet insurance is rare in most countries)
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Table 5 Costs related to the patient colonised or infected with resistant pathogen in human health, necessary in a “One-Health”
cost model
Data element Category of costs Cost items
Direct costs Costs of any treatment or prophylaxis of the
patient borne by the health service (regardless
of whether or not such costs are passed on to
the payor/insurance company).a
− Cost of antibiotics for treating infections
− Higher antibiotic expenses for empirical therapy due to a change in
guidelines in response to higher frequency of drug-resistant infections
− Cost of drug administration (central lines, etc.)
− Cost of nursing care
− Cost of cohorting (including cost of leaving not unoccupied beds due
to isolation of one patient restricting the use of the bed(s) in the same room)
− Extended length of stay, whereby ICU and non-ICU days should be separated
− Costs due to de-colonisation, if applicable, (e. g. mupirocin), re-testing,
e.g. additional follow-up screening
− Cost of non-standard surgical prophylaxis in colonised/infected patients, with
more expensive drugs
− Costs of infection prevention and control interventions as screening at
hospital admission or before surgery
Costs of long- term consequences of
AMR infection
− Cost of additional laboratory tests or imaging to diagnose site of infection or
foci of distant infectious metastatic foci
− Cost of diagnosing and treating adverse events to 2nd, 3rd line etc. (Drugs
used against MDROs infection need careful monitoring of toxicity and efficacy,
thus more laboratory and radiological tests.)
− Extra hospital admissions, or extra care for rehabilitation (e.g., respiratory,
mobility, cognitive, neurological) and/or treatments required for disease
sequelae directly linked to the drug-resistant infection, like recurrent
infection, kidney failure, amputation, neurological sequelae, extra surgery
Out-of-pocket expenditure borne by
the patient for care
− Transport to and from the hospital (if the sole reason for the hospital
admission was the infection)
− Cost of funeral in cases of (attributable) death
− Cost of (family/friend) care for the patient (e.g. hotel and meals to be
near the hospital) due to excess length of stay of the patient related
to the drug-resistant infection
Surveillance and control activitiesb − Costs of enhanced surveillance
− Cost of any screening that is triggered
− Costs of isolation, cohorting or contact precautions to the health care
system, including facility design and operational costs
Training of health care professionals and
information/communication
− Costs of pre-service, in-service and continuous professional education per
relevant cadre of human healthcare professional
− Cost of any related public health or information campaign
Legal and insurance costs (patient) − Additional insurance costs to cover problems associated specifically with
resistance
− Litigation costs, when suing hospitals for transmission of resistance infection
Legal and insurance costs (hospital) − Litigation costs, when sued by patients for transmission of resistance
infection
− Costs of implementing or regulating and enforcing national robust,
representative comprehensive surveillance programmes at all levels
of health care from primary to tertiary levels
Indirect costs Indirect patients’ costs: Loss of productivity/
earning/opportunity when seeking treatment
for the resistant infection (or colonisation)
or dying from the resistant infection
− Value of foregone workdays value of foregone workdays because of
disease sequelae related to the drug-resistant infection foregone
treatments that depend on effectiveness of prophylaxis, like surgical
interventions such as hip or knee replacements or caesarian sections
− Foregone leisure time (NB: difficult to quantify)
− Loss of productivity/earnings by family &visitors attending patient
− Loss of caretaker (family/friend) productivity – (workdays foregone)
− Psychological impact (factored in as QALY)
− Other costs related to different life style (e.g. amputation leading to
prosthesis or wheel chair; home renovation works to adapt to
disability; nursing care costs, if unable to perform activities)
Indirect hospital costs − Reduced patient turnover and decreased revenues (due to longer
hospital duration or to isolation/cohorting, or to decision not to
perform a non-essential procedure –e.g. cosmetic surgery - etc.)
− Reduced capacity of hospital (due to longer hospital duration or
to isolation/cohorting
− reputational costs borne by the hospital: any loss in hospital income
related to the level of resistant infection/colonisation
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Arguably this hinders to some extent our ability to
place AMR appropriately within the hierarchy of polit-
ical priorities and to address it with suitable urgency. An
important tool in communicating concerns about AMR
is to address the resulting economic consequences in a
comprehensive and more immediately relevant way [9].
In addition, while previous rough, top-down estimates
have helped ring the alarm bells within important inter-
national fora, they are insufficiently nuanced to help guide
decisions. If a common, bottom-up framework such as this
one can be applied in a selection of sites, we would be able
to collect the necessary data to communicate the import-
ance of AMR on the international and national agendas, in-
cluding the appropriate focus on the various settings and
sectors. Also, such cross-national estimates of costs within
these settings and sectors can help guide research and de-
velopment efforts, and appropriate funding schemes.
At national and local levels, a bottom-up costing is es-
sential for choosing the optimal way to tackle AMR. Nu-
merous different prevention, control, and treatment
measures are available to help combat AMR. However,
to compare existing measures or assess the potential of
new ones we need to be able to estimate the costs that
such interventions will impose as well as the costs that
their implementation will off-set (in addition to esti-
mates of their impact on the health burden). This
bottom-up cost framework is intended to facilitate the
estimation of these cost off-sets in particular, although
the One Health cost “ingredients” will also cover most of
the implementation costs associated with any interven-
tion and thereby make any intervention-related costing
exercise far simpler. Ultimately a bottom-up costing
framework should help simplify any eventual economic
analysis – whether it be cost-of-illness, cost-utility, or
cost-benefit in structure.
Challenges in isolating the costs of AMR
This work focusses on the additional cost of drug-
resistant infections and drug-resistant colonisation,
when compared to a drug-sensitive counterpart, answer-
ing the question “What is the impact of antibiotic-
resistant infections (or colonization) relative to the same
infection that would be susceptible to first line treat-
ments?”. Sometimes, comparison to non-infected pa-
tients would also apply; this is particularly relevant when
estimating the possible preventable burden of AMR,
while focusing on an intervention that eliminates resist-
ant as well as susceptible infections, like for example
vaccination. In this scenario the question “What is the
impact of antibiotic-resistant infections compared to a
situation in which such infections would not occur at all,
because they were prevented?” would be most relevant,
which would require a comparison to no infection .
When it comes to the costs associated with mortality,
the ability to attribute death to resistance is particularly
challenging.2
For some of the components, especially at popula-
tion level, attribution is fairly straightforward. For ex-
ample, costs associated with enhanced resistance
surveillance, consumption surveillance, public infor-
mation campaigns to guide consumption, are fully and
directly attributable to drug resistance. Other costs
such as those associated with novel antibiotic R&D
and antibiotic stewardship, infection control programs
and associated training and implementation and moni-
toring costs, are also attributable to resistance. How-
ever, for most other components, especially at the
individual level, attribution of cost to resistance is less
Table 5 Costs related to the patient colonised or infected with resistant pathogen in human health, necessary in a “One-Health”
cost model (Continued)
Data element Category of costs Cost items
Note that a reduction in visits to one hospital may simply
lead to an increase in visits for another. As this study takes
a societal perspective only overall net reduction should be
considered. (Assumption that no visits to the hospital are
superfluous so that a reduction in visits due to fear of
contracting a resistant pathogen imposes negative utility.)
Societal/government − Financial burden on the government for disability benefits
Research and development of new antibiotics − Cost to develop and bring a replacement drug to marketc
aIn sites where resistance is common and a greater percentage of fixed health care costs are spent managing it, the more the cost of overheads should be
included in cost equations. Note that most colonization will not be treated with drugs, except cases like MRSA in patients awaiting surgery. However, colonization
is likely to lead to more frequent visits, additional diagnostic tests, isolation of the patient, change in other contact precautions, etc.
bThis work considers costs associated with phenotypic resistance in most cases. In the case of resistance surveillance, it considers genotypic resistance in that
identification of resistance-carrying genes is assumed to impact on surveillance activities and screening in some cases
cWhen an antibiotic is rendered ineffective due to resistance, in a sense it is retired from the tool kit (in the language of accounting: it is fully depreciated). In
companies or governments, reserves would have been set aside to account for the eventual need to replace the key asset. If this replacement cycle is done well,
there is no downtime (for antibiotics, downtime is harm to patients from lack of effective therapy). So even if the antibiotic replacement cycle worked perfectly
(with no harm to patients) there still is a cost: the effort to bring a replacement drug successfully to market. There is significant social waste since drug developers
require many years (up to 15) from the university laboratory to an approved drug: it is difficult to judge the epidemiological need 15–-20 years onward. There
currently are many ongoing patent races, with some duplication of effort as well
2This challenge has been repeatedly brought to the fore in the
litigation of damage claims after death following resistant infection.
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clear. Methods to disentangle causation include sub-
jective, labour-intensive chart review, or objective,
costly cohort studies. In cohort studies, outcomes de-
riving from comparable patient groups with and with-
out the drug-resistant infection/colonisation of interest
are contrasted in order to measure the average additional
cost imposed by the resistant form of the infection.
Whether patients in the control groups should have a
drug-susceptible infection, or should have no infection, is
a subject of ongoing debate. Certain infections only hap-
pen because drug-resistance is present, like sepsis after an
inappropriately treated urinary tract infection, or a surgi-
cal site infection after standard prophylaxis. In this case, a
selection of control patients without infection is valid. For
other infections this is much less clear. In certain cases
the drug-resistant infection may just replace a drug-
susceptible infection, and a selection of control patients
with a drug-susceptible infection is most valid.
AMR costing studies will likely need to derive esti-
mates of attributable costs from cohort studies such as
those described above. Unfortunately, not many, high
quality studies exist, and often their external validity is
limited, leaving little precedent to utilize as a guide.
Furthermore, factors such as clinical manifestations –
the distinction between colonisation and infection -- can
add further layers of complexity when it comes to costs.
For example, if the vague colonisation status of the pa-
tient is known, this is likely to increase costs: prophylaxis
in the case of surgery or transplantation procedures
would require a highly effective broader spectrum agent,
which in many cases come with a higher price tag. Col-
onisation is also likely to lead to additional diagnostic
Table 6 Costs related to a companion animal colonized or infected with a resistant pathogen (using its owner as proxy), necessary
in a “One-Health” cost model
Data element Category of costs Individual costs
Direct Costs of any treatment of the animal borne
by the veterinary service (regardless of whether
or not such costs are passed on to an insurance
company.
− Cost of antibiotics
− Cost of drug administration (central lines, etc)
− Costs of diagnostic tests
− Cost of nursing care
− Cost of cohorting (including cost of leaving not
occupied beds due to isolation of one patient
restricting the use of the bed(s) in the same room)
− Extended length of stay
− Cost of non-standard surgical prophylaxis. Surgical
prophylaxis in infected patients, with more expensive
drugs
− Extra hospital admissions, or extra care required for
disease sequelae directly linked to the drug-resistant i
nfection, like recurrent infection, kidney failure,
amputation, neurological sequelae, extra surgery
Out-of-pocket expenditure borne by
the owner for care
− travel or transport to and from the veterinary clinic
− special food, physiotherapy, transport
− referring to specialists of complex cases
− pet health insurance
− Cost of disposal of remains/incineration/funeral
Surveillance and control activities − Costs of enhanced surveillance
− Cost of any screening that is triggered
− Costs of isolation, cohorting or contact precautions to
the veterinary health care system
− Costs for environmental decontamination of MDR bacteria
Training of health care professionals and
information/communication
− Costs of pre-service, in-service and continuous professional
education per relevant cadre of veterinary healthcare professional
− Cost of any related public health or information campaign
Legal and insurance costs (patient) − Additional insurance costs to cover problems associated
specifically with resistance
− Litigation costs, when suing hospitals for transmission
of resistance infection
Legal and insurance costs (hospital) − Litigation costs, when sued by patients for transmission
of resistance infection
− Costs of implementing or regulating and enforcing
national robust, representative comprehensive surveillance
programmes among companion animals
Indirect Loss of owner productivity when seeking
treatment for the animal’s resistant infection
(or colonisation) or when the animal dies
from the resistant infection
− value of foregone workdays
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tests, isolation of the patient, change in contact pre-
cautions (from standard precautions to standard plus
contact precautions), and other costs. Conversely,
while not knowing the colonisation status may lead to
lower assumed costs, the costs associated with a tran-
sition to unanticipated resistant infection might be
greater. The scenarios chosen to capture the different
possible health states and their respective probabilities
should reflect care realities at the local level (e.g. the
degree to which active screening is performed,
prophylaxis used, etc.).
The transmission of resistance within and between
communities today increases the risk of being colonized
and therefore further reduce the therapeutic options for
future patients.
Finally, it should be noted that to comprehensively
account for indirect costs may be particularly challen-
ging, as highlighted in a recent framework developed
to estimate the added value of new antibiotics in hu-
man health [22].
Pathogen selection
For the purposes of this initial framework the starting
point for selecting pathogen-drug pairs was the WHO
list of priority pathogens for which new research is most
urgently needed [23]. This was then expanded to include
all possible AMR resistant drug-pathogen pairs believed
to be most pressing for human, animal, and plant health,
excluding (for the present time) non-bacterial pathogens.
However, in practice, to maximize the usefulness of any
costing exercise the list of relevant pathogen-drug com-
binations must be made at a local level.
Also, while the choice was made to focus this frame-
work largely on bacterial microbes in the first instance,
following the WHO Global Action Plan [2], it should be
noted that the framework can be extended to fungal,
viral, and parasitic diseases, where drug-resistance is be-
coming increasingly important.
Finally, although a species perspective was taken in
this study, it is acknowledged that the microbiome, par-
ticularly those in the environment, include viable but
Table 7 Costs related to farm animals colonised or infected with resistant pathogens (using farmers as proxy), necessary in a “One-
Health” cost model
Data element Category of costs Individual costs
Direct Costs related to resistant infection or colonisation
with resistant bacteria within farm animals
− costs of 2nd, 3rd line antibiotic used for therapy vs growth
promotion vs prophylaxis/metaphylaxis
− Cost of veterinary consultation
− Costs of diagnostic work-up
− Reduction in farm productivity / output caused by AMR or
antimicrobial restriction/ban
Out-of-pocket expenditure by the farmer − any related animal transport, slaughter
− costs of culling animals
− Restocking with animals/eggs
Surveillance and control activities − Costs of enhanced surveillance
− Cost of any screening that is triggered
− Costs of isolation, cohorting or contact precautions
Legal and insurance costs − Insurance costs
− Litigation costs
− Costs due to penalties or taxes associated with antimicrobial
use; this is a reality in several EU countries (e.g. yellow card rule
and special taxes on certain antimicrobial products in Denmark)
Information and training costs − Cost of any AMR public health or information campaign
(e.g. including screening, biosecurity advising aimed at preventing
or managing animals with resistant infection)
− Costs of pre-service, in-service and continuous professional
education per relevant cadre of veterinary healthcare professional
and farm staff
Indirect costs Loss of productivity to the farm or the wider
food chain (if they are in some way dependent
on output from the AMR affected farm and
hence unable to maintain their normal level of
productivity/sales).a
− Reduction in individual farm productivity / output
− Longer time to market
− Reduction in farm productivity / impact on the food chain
(if food chain in some way dependent on output from the
AMR affected farm and hence unable to maintain the normal
level of productivity/sales)
− Reduction in sales following a lower demand that is caused
by knowledge of the existence of the resistant pathogen in
the food chain
Out-of-pocket expenditure by the consumer − Increased cost of meat and other animal food products as
a consequence of increased production costs
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not culturable (VNBC) bacteria that may also be reser-
voirs of resistance and resistance genes.
Limitations
In focusing on bacteria, this work ignores costs imposed
by resistance within other microorganisms. Even with
regard to bacteria, the list is not exhaustive, as only
major causes of disease/transmission/costs, were in-
cluded. In some parts of the world the most worrying
AMR will be amongst fungi, parasites, or viruses (e.g.
Plasmodium falciparum, or HIV,) – none of which are
explicitly listed in this work. In veterinary medicine an-
thelmintic resistance is an enormous problem already,
whereas antibacterial resistance is probably not yet
impacting on treatment of animal pathogens to the same
extent as in humans. Resistance to antifungals also im-
pose a non-negligible cost on healthcare services [24].
Recent examples include the global spread of Candida
auris infection and the azole-resistant Aspergillus fumi-
gatus [25, 26]. We hope to address the costs imposed by
these pathogens in future work.
Finally, in trying to create a framework that can be
used by researchers or government worldwide to
estimate the cost of AMR, this work is likely to miss
some important details in how and where AMR imposes
costs locally. Local studies may be needed to adapt the
framework to clinical norms and the epidemiological
reality to effectively capture costs.
A further challenge is the lack of research capacity and
funding, especially - but not only - in LMICs; the quality
and accuracy of the data necessary to obtain reliable cost
estimates is unlikely to be readily available in most
countries.
Conclusion and future developments
Attaining a realistic understanding of how and to what
extent antibiotic resistance affects society is a challen-
ging task. We hope that this work helps to pave the way
to a clearer view of AMR costs and ultimately helps in-
form important decisions across the interconnected do-
mains of human, animal, and environmental health in
the years to come. Whether these decisions concern po-
tential infection control interventions, targeting of sur-
veillance efforts, how best to steer research and
development efforts, or exciting innovative new ways of
tackling AMR, a credible and nuanced assessment of
Table 8 Costs to the environment, necessary in a “One-Health” cost model
Data element Category of costs Individual costs
Direct costs Cost of removing/decontaminating/cleaning/
stemming flow
− Drug production effluent
− Irrigation systems, farm run-off that contains resistant pathogens
− Relevant waste in waste management systems
− Relevant waste in drinking water storage and distributions systems
Costs of surveillance and control programmes − Costs of enhanced surveillance
− Cost of any screening that is triggered
− Cost of having to shift activities to non-contaminated areas
− Cost to authorities of enforcing penalties on industries
Training of food chain professionals (Environment) − Costs of pre-service, in-service and continuous professional
education per relevant cadre of environmental health professional
Legal and insurance costs − Cost to authorities of enforcing any penalties on industries
− Cost to industry to comply with AMR-related regulations
surrounding treatment, disposal, etc.
− Costs of implementing or regulating and enforcing national
environmental surveillance programmes on water, soil and air
in different components of the One Health triad as appropriate
Indirect costs Loss of productivity − Overall economic loss in having unusable land while
decontamination takes place (t.b.c.). Note this will be of
greater significance in countries that are densely populated,
densely apportioned economically (where the land is used to
the maximum extent for economic purposes), rely on
agriculture, and where water provision or flow is important
economic asset.
Loss to medical or non-medical trade and
tourism from reduced trade/tourism (e.g.
exclusion of a place as a tourist destination
explicitly due to AMR-related concerns)
− Loss in income from local tourism due to resistance in
swimming water, drinking water, any other contamination
(reputational costs).
− Loss to medical or non-medical trade and tourism from
reduced trade/tourism (e.g. exclusion of a place as a tourist
destination explicitly due to AMR-related concerns)
− Loss to the travel industry due to cancellations or to longer,
sustained reductions in travel
aAll types of productivity loss to the farm should be put together (again, individual from societal cost should not be separated to avoid double counting. Rather
the model will ultimately scale the effects of individual resistance up to where the more generalized societal costs come into play
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AMR-related costs is essential. Using a sufficiently
granular, bottom-up framework across multiple sites we
should be able to achieve the necessary global estimates
needed to support major international initiatives and
better guide major R&D funding, while remaining suffi-
ciently flexible to adapt to local realities and guide re-
source allocation.
Acknowledgements
We acknowledge Maria José Ruiz Alvarez from the Italian Ministry of Health,
and the JPIAMR Secretariat for their invaluable assistance throughout the
project.
Authors’ contributions
CM drafted the manuscript, LS coordinated the project, all other Authors
contributed with intellectual content to the project and the manuscript,
revised the final version and gave the final approval for submission.
Funding
The creation of the GAP-ONE Network was supported under the framework
of the Joint Programming Initiative on Antimicrobial Resistance and funded
by the Italian Ministry of Health, within the JPIAMR 8th call, Virtual Research
Initiative, 2018.
Availability of data and materials
Not applicable.





MdK received funding from the Innovative Medicines Initiative Joint
Undertaking under grant agreements nos. 115523, 115620, and 115737
(Combatting Bacterial Resistance in Europe projects [COMBACTE]), resources
of which are composed of financial contribution from the European Union’s
7th Framework Programme (FP7/2007 ± 2013) and the European Federation
of Pharmaceutical Industries and Associations (EFPIA) companies’ in kind
contribution. CA as a part of EU-JAMRAI (European Union Joint Action on
Antimicrobial Resistance and Healthcare-Associated Infections) has received
funding from the health programme of the European Union (2014-2020)
under grant agreement N°761296.
K.O. and R.A.A. was supported by the Cooperative Agreement Number IDSE
P160030 from ASPR/BARDA and by awards from Wellcome Trust, the Global
AMR Innovation Fund (GAMRIF) funded by the UK Government Department
of Health and Social Care (DHSC), the German Federal Ministry of Education
and Research (BMBF) and the Bill & Melinda Gates Foundation, as
administrated by CARB-X. The contents do not necessarily represent the
views of the CARB-X project nor any CARB-X project funder including the
governments of the United States (BARDA, NIAID), the United Kingdom
(DHSC, GAMRIF), or Germany (BMBF), the Wellcome Trust, or the Bill & Me-
linda Gates Foundation. KO is also supported by the Social Innovation on
Drug Discovery program at Boston University.
None of the other Authors have conflicting interests.
Author details
1GTGL University of Geneva, Geneva, Switzerland. 2CARB-X, Boston University,
Rockville, USA. 3Antimicrobial Resistance Centre, Norwegian Institute of
Public Health, Oslo, Norway. 4Infectious Disease Unit, Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico di Milano, Va Francesco Sforza, 28
Milano, Italy. 5Department of Pathophysiology and Transplantation, University
of Milano, Milan, Italy. 6Department of Management information and
production Engineering, Bergamo University, Bergamo, Italy. 7Drug science
Department, Pavia University, Pavia, Italy. 8Infectious Diseases, Department of
Diagnostic and Public Health, Univeristy of Verona, Verona, Italy. 9CEFAT -
Center of Pharmaceuticals Economics and Medical Technologies Evaluation,
Drug Science Department, Pavia University, Pavia, Italy. 10Infection Control
Program, Geneva University Hospitals and Faculty of Medicine, Geneva,
Switzerland. 11Antimicrobial Research Unit, College of Health Sciences,
University of KwaZulu-Natal, Durban, South Africa. 12Center for Disease
Dynamics, Economics & Policy, New Delhi, India. 13Antimicrobial Resistance
Unit, Department of Animal Health and VISAVET, Complutense University of
Madrid, Madrid, Spain. 14Laboratory Medical Microbiology, University of
Antwerp, Antwerp, Belgium. 15Department of Veterinary and Animal
Sciences, University of Copenhagen, Copenhagen, Denmark. 16Division of
Infectious Diseases, Geneva University Hospitals and Faculty of Medicine,
Geneva, Switzerland. 17Global Economic Dynamics and the Biosphere, Royal
Swedish Academy of Sciences, Stockholm Resilience Centre, Stockholm,
Sweden. 18Stockholm Resilience Centre, Stockholm University, Stockholm,
Sweden. 19Division of Infectious Diseases, Infection Control and prevention
program, Antimicrobial Stewardship program, AUBMC, Beirut, Lebanon.
20Veterinary Pathobiology, School of Veterinary Medicine, University College
Dublin, Dublin, Ireland. 21Infectious Diseases Unit, Hospital Durand, Buenos
Aires, Argentina. 22Infectious Diseases and Clinical Microbiology, Universidad
Maimónides Buenos Aires, Buenos Aires, Argentina. 23Division of Infectious
Diseases & HIV Medicine, Department of Medicine, Groote Schuur Hospital,
University of Cape Town, Cape Town, South Africa. 24Division of Infectious
Diseases, University of Genova and San Martino Hospital, Genova, Italy.
25Bonn University Hospital, Institute for Hygiene and Public Health, Bonn,
Germany. 26Infectious Diseases Division, Hospital Universitario Virgen
Macarena, Sevilla, Spain. 27Department of Medicine, University of Seville /
Biomedicine Institute of Seville, Sevilla, Spain. 28Internal Medicine I, Tübingen
University, Tübingen, Germany. 29IRCCS Policlinico San Matteo Foundation,
Pavia, Italy.
Received: 24 June 2020 Accepted: 22 September 2020
References
1. Transforming our world: the 2030 Agenda for Sustainable Development .:.
Sustainable Development Knowledge Platform. https://
sustainabledevelopment.un.org/post2015/transformingourworld. Accessed
11 Dec 2019.
2. WHO. GLOBAL ACTION PLAN ON ANTIMICROBIAL' ' RESISTANCE. 2015.
3. EU Commission. A European One Health Action Plan against Antimicrobial
Resistance (AMR). https://ec.europa.eu/health/sites/health/files/
antimicrobial_resistance/docs/amr_2017_action-plan.pdf. Accessed 9 Oct
2020.
4. Smith E. Evaluation of the EC Action Plan against the rising threats from
antimicrobial resistance. EU commission; 2016.
5. Drug-Resistant Infections: A Threat to Our Economic Future. https://www.
worldbank.org/en/topic/health/publication/drug-resistant-infections-a-
threat-to-our-economic-future. Accessed 25 Feb 2020.
6. Food and Agriculture Organization of the United Nations. Antimicrobial
Resistance. What is it? http://www.fao.org/antimicrobial-resistance/
background/what-is-it/en/. Accessed 9 June 2018.
7. Cecchini M, Langer J, Slawomirski L. Antimicrobial Resistance' ' in G7
countries and beyond economic issues, Policies and Options for Action .
OECD; 2015.
8. OECD, WHO, OIE, FAO. Tackling antimicrobial resistance: ensuring
sustainable R&D. 2017.
9. The Review on Antimicrobial Resistance, chaired by Jim O’Neill. TACKLING
DRUG-RESISTANT' ' INFECTIONS GLOBALLY: FINAL REPORT AND
RECOMMENDATIONS. 2016.
10. RAND corporation JT, Marco Hafner, Erez Yerushalmi, Richard Smith, Jacopo
Bellasio, Raffaele Vardavas, Teresa Bienkowska-Gibbs, Jennifer Rubin.
Estimating the economic costs of antimicrobial resistance. Model and
Results. RAND corporation; 2016.
11. The World Bank. Drug resistant Infections. A Threat to Our Economic Future
(Discussion draft). The World Bank; 2016.
12. GAP-ONE. https://www.jpiamr.eu/gap-one/. Accessed 30 Dec 2019.
13. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The
REDCap consortium: Building an international community of software
platform partners. J Biomed Inform. 2019;95:103208. https://doi.org/10.1016/
j.jbi.2019.103208.
14. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL,
et al. Discovery, research, and development of new antibiotics: the WHO
Morel et al. Antimicrobial Resistance and Infection Control           (2020) 9:187 Page 13 of 14
priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis.
2018;18:318–27. https://doi.org/10.1016/S1473-3099(17)30753-3.
15. Background: About the Canadian Integrated Program for Antimicrobial




16. Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ. Epidemiological
interpretation of studies examining the effect of antibiotic usage on
resistance. Clin Microbiol Rev. 2013;26:289–307. https://doi.org/10.1128/CMR.
00001-13.
17. Corbella M, Caltagirone M, Gaiarsa S, Mariani B, Sassera D, Bitar I, et al.
Characterization of an outbreak of extended-Spectrum β-lactamase-
producing Klebsiella pneumoniae in a neonatal intensive care unit in Italy.
Microb Drug Resist. 2018;24:1128–36. https://doi.org/10.1089/mdr.2017.0270.
18. Snyder GM, Young H, Varman M, Milstone AM, Harris AD, Munoz-Price S.
Research methods in healthcare epidemiology and antimicrobial
stewardship-observational studies. Infect Control Hosp Epidemiol. 2016;37:
1141–6. https://doi.org/10.1017/ice.2016.118.
19. Aarestrup FM. The livestock reservoir for antimicrobial resistance: a personal
view on changing patterns of risks, effects of interventions and the way
forward. Philos Trans R Soc Lond B, Biol Sci. 2015;370:20140085. https://doi.
org/10.1098/rstb.2014.0085.
20. WHO | Joint FAO/WHO Expert Meeting in collaboration with OIE on
Foodborne Antimicrobial Resistance: Role of the Environment, Crops and
Biocides. https://www.who.int/foodsafety/publications/Environment-Crops-
and-Biocides/en/. Accessed 30 Dec 2019.
21. Living with Resistance project. Antibiotic and pesticide susceptibility and
the Anthropocene operating space. Nat Sustain. 2018;1:632–41. https://doi.
org/10.1038/s41893-018-0164-3.
22. Implications of alternative funding arrangements for NICE Appraisal. https://
www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-
bacteria/en/. Accessed 9 Oct 2020.
23. Global priority list of antibiotic-resistant bacteria to guide research,
discovery, and development of new antibiotics. https://www.who.int/
medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/.
24. Muñoz P, Valerio M, Vena A, Bouza E. Antifungal stewardship in daily
practice and health economic implications. Mycoses. 2015;58(Suppl 2):14–
25. https://doi.org/10.1111/myc.12329.
25. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A, et al.
Candida auris: a review of the literature. Clin Microbiol Rev. 2018;31. https://
doi.org/10.1128/CMR.00029-17.
26. Verweij PE, Chowdhary A, Melchers WJG, Meis JF. Azole resistance in
Aspergillus fumigatus: can we retain the clinical use of Mold-active
antifungal azoles? Clin Infect Dis. 2016;62:362–8. https://doi.org/10.1093/cid/
civ885.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Morel et al. Antimicrobial Resistance and Infection Control           (2020) 9:187 Page 14 of 14
